 Co-Diagnostics NASDAQ:CODX Inc., which has a patented platform for the development of molecular diagnostic tests, revealed that none of the mutations in the heavily mutated SARS-CoV-2 variant recently discovered in Africa are expected to interfere with any of its suite of coronavirus COVID-19 PCR diagnostic assays. The Salt Lake City, Utah-based molecular diagnostics company said that the new coronavirus strain includes more than 50 mutations, over 30 of which are found on the viruss spike protein, the main target of the bodys immune responses, and is currently being studied to determine whether the mutations lead to increased transmissibility, or ability to evade the bodys immune response. 